SCHEMBL440365

SCHEMBL440365

C[C@@H](N)Cc1nc[nH]c1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 1/20 0.41
KDM4E B2RXH2 2/20 0.40
HRH4 Q9H3N8 4/20 0.39
HRH3 Q9Y5N1 4/20 0.39
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 1/20 0.39
GLA P06280 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 1/20 0.39
NFKB1 P19838 1/20 0.39
THPO P40225 1/20 0.39
LMNA P02545 3/20 0.38
APEX1 P27695 1/20 0.38
BLM P54132 1/20 0.38
GDA Q9Y2T3 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.35
CYP3A4 P08684 1/20 0.35
SLC7A5 Q01650 1/20 0.35
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11411483 0.77 GABRR1 (0.37) GABRR1KDM4EBLMGDACYP2C19
SCHEMBL11389117 0.77 KDM4E (0.49) GABRR1KDM4EHRH4HRH3ALDH1A1
Hydrochloric Acid SCHEMBL947746 0.75 KDM4E (0.47) GABRR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2790547 0.73 GABRR1 (0.61) GABRR1KDM4EALDH1A1CYP1A2NFKB1
SCHEMBL23930811 0.73 GABRR1 (0.43) GABRR1KDM4EALDH1A1LMNAGDA
SCHEMBL2627830 0.69 KDM4E (0.41) GABRR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL18599226 0.67 GDA (0.40) GABRR1KDM4EALDH1A1LMNAGDA
SCHEMBL2815970 0.67 GABRR1 (0.57) GABRR1HRH4HRH3ALDH1A1MEN1
SCHEMBL2815963 0.67 GABRR1 (0.57) GABRR1HRH4HRH3ALDH1A1MEN1
SCHEMBL101340 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230116385-A1 COMPOSITION OF A THERAPEUTIC OLIGOMER Sachi Bioworks Inc. (US) 2023-04-13 US disclosed
US-11155631-B2 Macromolecular compositions that cross the blood-brain barrier and methods of use thereof ARMAGEN, INC. (US) 2021-10-26 US disclosed
CN-112730695-A Method for measuring content of amino acid in fresh tobacco leaves 云南中烟工业有限责任公司 2021-04-30 CN disclosed
US-10144783-B2 Macromolecular compositions that cross the blood-brain barrier and methods of use thereof ARMAGEN, INC. (US) 2018-12-04 US disclosed
EP-2051734-B1 AGENTS FOR BLOOD-BRAIN BARRIER DELIVERY ARMAGEN TECHNOLOGIES INC (US) 2016-10-05 EP disclosed
US-9315851-B2 Methods, peptides, and biosensors useful for detecting a broad spectrum of bacteria WOUNDCHEK LABORATORIES (US), INC. (US) 2016-04-19 US disclosed
EP-2255826-B1 NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS GLAXOSMITHKLINE BIOLOG SA (BE) 2016-04-13 EP disclosed
US-20160082097-A1 NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS GLAXOSMITHKLINE BIOLOG SA (BE) 2016-03-24 US disclosed
US-20150203586-A1 MACROMOLECULAR COMPOSITIONS THAT CROSS THE BLOOD-BRAIN BARRIER AND METHODS OF USE THEREOF ARMAGEN, INC. 2015-07-23 US disclosed
US-20150184220-A1 Methods, Peptides, and Biosensors Useful for Detecting a Broad Spectrum of Bacteria WOUNDCHEK LAB US INC (US) 2015-07-02 US disclosed
EP-1078063-A2 BASB029POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM NEISSERIA MENINGITIS SmithKline Beecham Biologicals s.a. (BE) 2001-02-28 EP disclosed
EP-1073747-A1 BASB013 DNA AND PROTEINS FROM NEISSERIA MENINGITIDIS SMITHKLINE BEECHAM BIOLOGICALS s.a. (BE) 2001-02-07 EP disclosed
EP-1071783-A2 BASB006 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM NEISSERIA MENINGITIS SMITHKLINE BEECHAM BIOLOGICALS s.a. (BE) 2001-01-31 EP disclosed
WO-2000015801-A1 POLYNUCLEOTIDES AND POLYPEPTIDES BASB033 FROM NEISSERIA MENINGITIDIS AND THEIR USES SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) 2000-03-23 WO disclosed
WO-2000011182-A1 BASB024 OUTER MEMBRANE PROTEIN OF NEISSERIA MENINGITIDIS SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) 2000-03-02 WO disclosed
WO-1999061620-A2 NEISSERIA MENINGITIDIS ANTIGENIC POLYPEPTIDES, CORRESPONDING POLYNUCLEOTIDES AND PROTECTIVE ANTIBODIES SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) 1999-12-02 WO disclosed
WO-1999058683-A2 BASB029 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM $i(NEISSERIA MENINGITIDIS) SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) 1999-11-18 WO disclosed
WO-1999055872-A1 BASB013 DNA AND PROTEINS FROM NEISSERIA MENINGITIDIS SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) 1999-11-04 WO disclosed
WO-1999055873-A2 BASB006 POLYNUCLEOTIDE(S) AND POLYPEPTIDES FROM NEISSERIA MENINGITIS SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) 1999-11-04 WO disclosed
CN-1182432-A Human neuropeptide receptor HUMAN GENOME SCIENCES INC (US) 1998-05-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160082097-A1 NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS NASP, SPAG5, ANTXR2 GABRR1 3363/4885KDM4E 4458/4885HRH4 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.